Business Wire

NY-GARIA

5.10.2021 16:55:09 CEST | Business Wire | Press release

Share
Viridi Parente Partners with Garia to Bring Last Mile, Low-Speed Electric Utility Vehicles to the United States

Viridi Parente, Inc., a developer of innovative battery technology that can be safely installed and operated in nearly any environment or location, is partnering with Garia Utility , the Denmark-based leader in low-speed utility vehicles , to develop last-mile , low-speed electric utility vehicles for the U.S. market. These vehicles will be manufactured in Buffalo, New York, and branded under the Green Machine Equipment name.

An image of the Green Machine electric, low-speed utility vehicle may be downloaded here - https://rb.gy/uywc9e .

"If we are going to have any impact on decarbonization, we need to rethink our supply chain strategies and equipment options, especially for last-mile delivery," said Jon M. Williams, CEO of Viridi Parente. "Green Machine couldn't ask for a better partner to introduce clean utility vehicles into the U.S. than Garia. Its proven technology is already deployed throughout Europe, and the compact design is ideally suited for use in dense, urban areas in the U.S."

Garia chose to partner with Green Machine because of its proprietary, durable, and safe battery technology that is being used by leading construction brands such as Bobcat and Case . Green Machine was the first manufacturer to introduce all-electric heavy construction and industrial equipment into the market and has perfected the technology with more than 250,000 hours of robust field testing.

Garia Utility has over 900 last-mile vehicles deployed on delivery routes in Sweden through a contract with PostNord (the Swedish Postal Service). The combination of Green Machine's propriety technology and Garia's know-how in the last-mile vehicle space creates a superb clean vehicle that replaces standard diesel or gasoline-powered utility vehicles . For U.S. markets, Green Machine battery technology will increase the range and adaptability of the vehicle.

"After evaluating many potential partners, Viridi Parente was the obvious choice," said Jakob Holstein, CEO of Garia. "Not only did they have the best technology for our needs, but their technology had the most field experience. We were also aligned well on leadership and values."

Green Machine's electric utility vehicles are unlike anything currently available in the U.S. The compact design allows users to access narrow spaces such as constricted roadways, tight alleys, or compressed park or campus pathways. In addition to the traditional model, Green Machine has installed its technology into a right-hand-drive chassis from Garia that squarely fits any delivery needs.

Still dominated by fossil-fuel-powered trucks and vehicles, the supply chain remains a significant source of greenhouse gasses. In New York, transportation accounts for about 36% of the state's carbon emissions. While the nation's reliance on an efficient, reliable supply chain increases, so does the desire to transition long-haul and last-mile delivery to zero-emission vehicle options. McKinsey forecasts that the number of electric utility vehicles will grow from just 5,000 in 2018 to more than 8 million by 2030.

About Viridi Parente

Viridi Parente (Viridi) is a disruptive energy company in Buffalo, New York, that is changing the way we use energy, improving systems, communities, and lives. Viridi deploys safe battery technology into applications that have been historically dominated by fossil fuel energy sources. Its innovative architecture is constructed from materials used for aerospace and military applications and is the only design in the market that can be safely installed and operated in nearly any environment or location. Through its subsidiary, Green Machine Equipment, Viridi is bringing quiet, fully renewable mobile energy solutions to products in construction equipment, waste disposal, last-mile delivery, and other portable industrial markets. Through its subsidiary, Volta Energy Products, Viridi brings stationary, point-of-use storage technology that is safe, locatable, and reliable to industrial, medical, commercial, municipal, and residential building applications. Learn more at: www.viridiparente.com .

About Garia A/S

Garia is a manufacturer of utility vehicles, premium golf, and leisure cars. Founded in 2005 by Anders Lynge, Garia is privately held by Lars Larsen Group and headquartered in Denmark with a subsidiary in the U.S.

In 2015, with ten years of experience in the luxury electric vehicle market, Garia embarked on an entirely new journey: the Garia Utility. A compact electric utility vehicle that combines reliability, ergonomics, and zero emissions with comfort, functionality, and thoughtful design. Made of high-quality European components, the Garia Utility is one of a kind.

Learn more about the Garia Utility at gariautility.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye